In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity

Blood

Volumn 112, Issue 6, 2008, Pages 2563-2574

  Nishimura, Ryosei ^a   Baker, Jeanette ^a   Beilhack, Andreas ^a,b   Zeiser, Robert ^a   Olson, Janelle A ^a   Sega, Emanuela I ^a   Karimi, Mobin ^a   Negrin, Robert S ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; CYTOKINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DIVISION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MINOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; ADOPTIVE TRANSFER; ANIMAL; CELL CULTURE; CONGENIC STRAIN; CULTURE TECHNIQUE; CYTOLOGY; CYTOTOXICITY; IMMUNOLOGY; METHODOLOGY; MOUSE STRAIN; NEOPLASM; NEUTROPHIL CHEMOTAXIS; STANDARD; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GRAFT VS HOST DISEASE; KILLER CELLS, NATURAL; MICE; MICE, CONGENIC; MICE, INBRED STRAINS; NEOPLASMS; T-LYMPHOCYTES;

EID: 55249095629     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-06-092817     Document Type: Article

References (37)

1. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissrnan IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139-149.
2. + NK-T cells in humans and mice. J Clin Immunol. 2002;22:131-136.
3. + cells from peripheral blood progenitor cells of patients undergoing autologous hemato poietic cell transplantation. Biol Blood Marrow Transplant. 2001;7:216-222.
4. Linn YC, Lau LC, Hui KM. Generation of cytokineinduced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002;116:78-86.
5. Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993;21:1673-1679.
6. + T cells. Blood. 2004;103:3065-3072.
7. + T cells and NK cells. J Immunol. 2005;175:7819-7828.
8. Edinger M, CaoYA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003:101:640-648.
9. Baker J, Verneris M R, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001;97:2923-2931.
10. Cao YA, Wagers AJ, Beilhack A, et al. Shifting foci of hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci U S A. 2004;101:221-226.
11. + regulatory T cells preserve graftversus-tumor activity while inhibiting graftversus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144-1150.
12. BeilhackA, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106:1113-1122.
13. Lerner KG, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc. 1974;6:367-371.
14. Lin MT, Tseng LH, Frangoul H, et al. Increased apoptosis of peripheral blood T cells following allogeneic hematopoietic cell transplantation. Blood. 2000;95:3832-3839.
15. Jaksch M, Remberger M, Mattsson J. Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:280-287.
16. Sackstein R. A revision of Billingharrrs tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12:2-8.
17. Yang YG, Qi J, Wang MG, Sykes M. Donorderived interferon gamma separates graftversus-leukemia effects and graft-versus-host disease induced by donor CDS T cells. Blood. 2002;99:4207-4215.
18. Asai O, Longo DL, Tian ZG, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998:101:1835-1842.
19. Fujioka T, Taniguchi Y, Masuda T, et al. The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model. Transpl Immunol. 2003;11:187-195.
20. Liu Y, Janeway CA Jr. Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J Exp Med. 1990;172:1735-1739.
21. Waldman E, Lu SX, Hubbard VM, et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood. 2006;107: 1703-1711.
22. Welniak LA, Wang Z, Sun K, et al. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. Exp Hematol. 2004; 32:318-324.
23. Duffner U, Lu B, Hildebrandt GC, et al. Role of CXCRS-induced donor T-cell migration in acute GVHD. Exp Hematol. 2003;31:897-902.
24. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graftversus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389-399.
25. + regulatoryT cells. Blood. 2005;105:4743-4748.
26. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M. Large-scale in vitro expansion of polyclonal human GD4(+)CD25high regulatoryT cells. Blood. 2004;104:895-903.
27. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.
28. Jarvis LB, Matyszak MK, Duggleby RC, Goodall JC, Hall FC. Gaston JS. Autoreactive human peripheral blood CD8+ T cells with a regulatory phenotype and function. Eur J Immunol. 2005;35: 2896-2908.
29. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171:1272-1277.
30. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J Immunol. 1999;162:6368-6377.
31. Coudert JD, Held W. The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol. 2006;16:333-343.
32. Zhang S, Wang Q, Li WF, Wang HY, Zhang HJ. Enhanced antitumor immunity by murine cytokine activated T lymphocytes after cocultured with bone marrow derived dendritic cells pulsed with whole tumor lysates. Leuk Res. 2004;28:1085-1088.
33. Chan JK, Hamilton CA, Cheung MK, et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res. 2006;12:1859-1867.
34. Verneris MR, Arshi A, Edinger M, et al. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res. 2005;11:4561-4570.
35. Thome SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science. 2006;311:1780-1784.
36. LeemhuisT, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokineinduced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11:181-187.
37. Introna M, Borleri G, Conti E, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007;92:952-959.